Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity.

Minor DR, Madland MT, Kashani-Sabet M, Denny SR, Harvey WB.

Cancer Biother Radiopharm. 2005 Oct;20(5):479-86.

PMID:
16248763
2.
3.

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.

Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, Parker RA, Mier JW.

Clin Cancer Res. 2002 Oct;8(10):3075-81.

4.

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.

McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB.

Clin Cancer Res. 2000 Jun;6(6):2201-8.

5.

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS.

J Clin Oncol. 2002 Apr 15;20(8):2045-52.

PMID:
11956264
6.

Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases.

Buzaid AC, Colome M, Bedikian A, Eton O, Legha SS, Papadopoulos N, Plager C, Ross M, Lee JE, Mansfield P, Rice J, Ring S, Lee JJ, Strom E, Benjamin R.

Melanoma Res. 1998 Dec;8(6):549-56.

PMID:
9918417
7.

Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.

González Cao M, Malvehy J, Martí R, Conill C, Sánchez M, Martín M, Carrera C, Herrero J, Gascón P, Mellado B, Castel T, Puig S.

Melanoma Res. 2006 Feb;16(1):59-64.

PMID:
16432457
8.

Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.

O'Day SJ, Atkins MB, Boasberg P, Wang HJ, Thompson JA, Anderson CM, Gonzalez R, Lutzky J, Amatruda T, Hersh EM, Weber JS.

J Clin Oncol. 2009 Dec 20;27(36):6207-12. doi: 10.1200/JCO.2008.20.3075.

PMID:
19917850
9.

Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.

Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, Bedikian AY.

Cancer. 2004 Aug 1;101(3):596-603.

10.
11.

Biochemotherapy in the treatment of metastatic melanoma in selected patients.

González Astorga B, Jiménez Rubiano B, Delgado Pérez JR, Valdivia Bautista J, Sánchez Toro C, González Flores E, Luque Caro R, Castellón Rubio V.

Clin Transl Oncol. 2009 Jun;11(6):382-6. Review.

PMID:
19531453
12.

Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes.

Håkansson A, Gustafsson B, Krysander L, Hjelmqvist B, Rettrup B, Håkansson L.

Br J Cancer. 2001 Dec 14;85(12):1871-7.

13.

A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.

Gibbs P, Iannucci A, Becker M, Allen J, O'Driscoll M, McDowell K, Williams P, Rosse P, Murphy J, Gonzalez R.

Melanoma Res. 2000 Apr;10(2):171-9.

PMID:
10803718
14.

Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma.

O'Day SJ, Gammon G, Boasberg PD, Martin MA, Kristedja TS, Guo M, Stern S, Edwards S, Fournier P, Weisberg M, Cannon M, Fawzy NW, Johnson TD, Essner R, Foshag LJ, Morton DL.

J Clin Oncol. 1999 Sep;17(9):2752-61.

PMID:
10561350
15.

Clinical results using biochemotherapy as a standard of care in advanced melanoma.

Chapman PB, Panageas KS, Williams L, Wolchok JD, Livingston PO, Quinn C, Hwu WJ.

Melanoma Res. 2002 Aug;12(4):381-7.

PMID:
12170188
16.

Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma.

Recchia F, Candeloro G, Necozione S, Fumagalli L, Bratta M, Rea S.

Anticancer Drugs. 2008 Feb;19(2):201-7. doi: 10.1097/CAD.0b013e3282f2c0bc.

PMID:
18176117
17.

Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma.

Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, Bassett R Jr, Hwu WJ, Bedikian AY, Davies MA, Woodman SE, Hwu P.

Melanoma Res. 2014 Aug;24(4):342-8. doi: 10.1097/CMR.0000000000000062.

18.
19.
20.

A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.

Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY.

Melanoma Res. 2009 Feb;19(1):42-9. doi: 10.1097/CMR.0b013e328314b84a.

PMID:
19430405
Items per page

Supplemental Content

Support Center